Skip to main content

Table 1 Patient characteristic. Treatment and clinical outcome data for all patients with approved MR spectra.

From: Metabolic profiling of human brain metastases using in vivo proton MR spectroscopy at 3T

Patient no.

Sex, Age

Primary cancer

Brain mets

Mets other sites than brain

KPS

RPA

Survival (months)

Treatment

Time: diagnosis- 1.MRS (weeks)

Spectral data TE, VOI1,2

1

F, 52

Breast

Single

Brain only

90

1

13+

S + 3Gyx10

5

32,1441

2

M, 44

Lung

Single

Brain only*

90

1

10+

S

1

33,1442

3 a

F, 47

Lung

Multiple

Brain only

90

1

7+

C

0

32,1441

4 a

F, 45

Breast

Multiple

Mediastinum

100

2

15+

S + 3Gyx10

1

33,1442

5 a

F, 48

Breast

Multiple

Skeleton*

100

2

5+

3Gyx10

0

332

6

F, 57

Lung

Multiple

Intestinal, jejunum

100

2

7

3Gyx10

4

32,1441

7

M, 63

Lung

Multiple

Lung, skeleton

100

2

6

3Gyx10

2

32,1441

8

M, 62

Lung

Single

Skeleton

90

2

4.5

S + 3Gyx10

4

33,1442

9

M, 70

Mal. mel.

Multiple

Lung, subcutan*

90

2

2

S + 3Gyx10

3

33 in 2 VOI2

10

F, 36

Breast

Multiple

Liver, skeleton

80

2

9

4Gyx5 (GK)

1

32,1441

11

F, 47

Breast

Multiple

Liver

80

2

10

3Gyx10

2

32,1441

12 b

F, 66

Breast

Multiple

Brain only

80

2

2

3Gyx10

3

33 in 2 VOI2

13

M, 70

Colon

Single

Liver, lung

80

2

6

S + 4Gyx5

17

33,1441

14 b

F, 80

Lung

Multiple

Brain only

80

2

0.75

4Gyx5

1

33 in 2 VOI2

15 a

F, 71

Lung

Multiple

Brain only

80

2

3

3Gyx10

4

33 in 2 VOI2

16

F, 72

Breast

Multiple

Liver, skeleton

60

3

0.5

4Gyx5

2

33,1442

17

M, 69

Colon

Single

Liver, lung

60

3

6

S + 3Gyx10

5

32,1441

18 a

F, 53

Lung

Multiple

Brain only*

60

3

11+

4Gyx5

2

33 in 2 VOI2

19

M, 56

Mal. mel.

Multiple

Epigastrium

60

3

1

No Treatment

2

332 and 321

20

F, 63

Breast

Single

Lung, skeleton, lymph node

50

3

0.5

No treatment

0

33,1442

21

F, 71

Mal. mel.

Single

Lung, liver

50

3

1.5

3Gyx10

8

32,1441

  1. F = female, M = male, mets = metastases, a: three MRS follow-up examinations, b: two follow-up MRS examinations, *: brain metastases detected before primary cancer, KPS = Karnofsky Performance Score, RPA = Recursive Partitioning Analysis classification, TE = echo time, VOI1,2 = volume of interest, 1: voxel size: 15 × 15 × 15 mm3, 2: 10 × 10 × 10 mm3. Mal. mel. = malignant melanoma, GK = gamma knife, S = Brain surgery and histopathologic verification, C = Chemotherapy.